Lantern Pharma Q2 2023 net loss $4.7M; cash $48.0M; LP-184 IND cleared, LP-284 IND imminent

Lantern Pharma Inc.

2023-Q2 EPS reported -$0.79

Cash and equivalents $48.0M at June 30, 2023 ($55.2M at Dec 2022); cash runway into 2025.
Net loss $4.7M ($0.44/shr) vs $4.5M ($0.41/shr) in Q2 2022; R&D expenses up to $3.6M from $3.0M.
FDA cleared IND for LP-184; Phase 1 basket trial activated for solid tumors and brain cancers.
LP-284 IND submission expected August 2023; Phase 1 trial targeted for Q4 in non-Hodgkin's lymphomas.
Dosed first patients in Phase 2 Harmonic trial for never-smoker NSCLC; RADR collaboration with Bielefeld University for ADCs.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.65

Lantern Pharma Inc. reported financial results for the second quarter ended June 30, 2023.

Period: the second quarter ended June 30, 2023
Result: reported results

Exact text from the filing

Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the second quarter ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

Lantern Pharma Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-027346

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.